Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib
| Autor: | Nazım Can Demircan, K İşsever, Irfan Cicin, Ahmet Kucukarda, S Solak, Ali Gökyer, Bulent Erdogan, B S Sunal, Osman Kostek, Sernaz Uzunoglu, Muhammet Bekir Hacioglu |
|---|---|
| Přispěvatelé: | Gokyer, A, Kucukarda, A, Kostek, O, Hacioglu, MB, Sunal, BS, Demircan, NC, Uzunoglu, S, Solak, S, Issever, K, Cicin, I, Erdogan, B, Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü, Gökyer, Ali, Erdoğan, Bekir |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Male Cancer Research medicine.medical_specialty Sarcopenia Colorectal cancer Pyridines Kaplan-Meier Estimate Gastroenterology 03 medical and health sciences Drug withdrawal Basal (phylogenetics) chemistry.chemical_compound 0302 clinical medicine Internal medicine Regorafenib medicine Humans In patient Aged Retrospective Studies Mucous Membrane business.industry Phenylurea Compounds General Medicine Exanthema Middle Aged musculoskeletal system medicine.disease Rash Progression-Free Survival 030104 developmental biology Oncology chemistry 030220 oncology & carcinogenesis Toxicity Hypertension Female Hand-Foot Syndrome Disease Susceptibility medicine.symptom business Colorectal Neoplasms Tomography X-Ray Computed human activities |
| Zdroj: | Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 21(11) |
| ISSN: | 1699-3055 |
| Popis: | BackgroundSarcopenia is related to poor prognosis and drug toxicities in solid tumors. The aim of our study is to investigate the predisposition of patients with metastatic colorectal carcinoma who started regorafenib treatment to sarcopenia and prolonged survival.MethodsPatients with metastatic colorectal carcinoma who receives regorafenib were search retrospectively. Dose-limiting toxicity was defined as dose reduction or toxicity requiring drug withdrawal. Sarcopenia evaluation was made with computed tomography performed within a month before treatment. Progression-free survival and overall survival were estimated.ResultsThirty-six patients were found as suitable for the study. 63.9% of patients were found as basally sarcopenic. Dose-limiting toxicity occured 13 of 23 patients (56.5%) with basal sarcopenia, whereas only 1 of 13 patients (7.6%) with no sarcopenia exhibited dose-limiting toxicity (p=0.005). Three patients suffered from grade 3-4 toxicity. Hand-foot syndrome, hypertension, and mucosal rash were the most seen side effects. Mean regorafenib treatment duration was 3.36 months. There was no significant difference in the progression-free survival (PFS) and the overall survival (OS) between sarcopenic patients and patients with no sarcopenia. Durations were as OS 24.2 weeks in patients with sarcopenia (95% CI 16.7-31.7), 28.1 weeks in patients with no sarcopenia (95% CI 20.5-35.7) (p=0.36), and as PFS 14.2 weeks in patients with sarcopenia (95% CI 12.1-16.4), 14.8 weeks in patients with no sarcopenia (95% CI 9.7-20.1) (p=0.65).ConclusionDose-limiting toxicity was significantly higher in basally sarcopenic patients who were started regorafenib as treatment of metastatic colorectal carcinoma. There was no significant relationship between overall survival and progression-free survival with sarcopenia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink